The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications

08-Sep-2015 | Source : RXi Pharmaceuticals | Visits : 6289
MARLBOROUGH, Mass. - RXi Pharmaceuticals Corporation today announced in a press release that it has been granted a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the methods of use of siRNA sequences targeting vascular endothelial growth factor (VEGF). The patent, part of RXi's acquired OPKO estate, is scheduled to expire in 2022 and may become eligible for Patent Term Extension (PTE) subject to certain conditions being met.

RNAi compounds targeting these VEGF sequences may be beneficial for the treatment of neovascularization disorders, including wet age-related macular degeneration (AMD) and diabetic retinopathy. RNAi compounds targeting these sequences also have the potential to be useful in combination with RXI-109 which could address both the neovascularization and scarring components encountered in AMD.

"This Notice of Allowance from the USPTO for these sequences expands and strengthens our intellectual property estate in the anti-VEGF area, which includes ophthalmology, one of our seven core initiatives to increase shareholder value," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He further added, "With the recent activation of our ophthalmology IND, and with this Notice of Allowance, we not only increase the value proposition of our Ophthalmology Franchise for our shareholders and potential business partners, we also expand and improve our intellectual property position for strategic partnering of our self-delivering technology platform in other therapeutic areas."

RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs. 

Related Articles